Kura Oncology Inc Market Cap ($676.99 Million)
Market Cap & Net Worth: Kura Oncology Inc (KURA)
Kura Oncology Inc market cap. Kura Oncology Inc (NASDAQ:KURA) has a market capitalization of $676.99 Million ($676.99 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10426 globally and #2799 in its home market, demonstrating a -23.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kura Oncology Inc's stock price $7.61 by its total outstanding shares 88960619 (88.96 Million). Also see Kura Oncology Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Kura Oncology Inc Market Cap History (2015–2026)
Kura Oncology Inc market cap history from 2015 to 2026. Data shows change from $747.27 Million to $676.99 Million (-5.37% CAGR). Check Kura Oncology Inc share price for real-time trading data and today's change.
Index Memberships
Kura Oncology Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #292 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1085 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #173 of 263 |
Weight: Kura Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kura Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kura Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KURA net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
13.70x
Kura Oncology Inc's market cap is 13.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $774.85 Million | $53.88 Million | -$173.98 Million | 14.38x | N/A |
| 2025 | $924.30 Million | $67.48 Million | -$278.67 Million | 13.70x | N/A |
Competitor Companies of KURA by Market Capitalization
Companies near Kura Oncology Inc in the global market cap rankings as of November 5, 2026. Also see Kura Oncology Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Kura Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Kura Oncology Inc (2015–2026)
Market capitalization of Kura Oncology Inc from 2015 to today. Between 2015 and today, Kura Oncology Inc's market cap moved from $747.27 Million to $ 676.99 Million, with a yearly change of -5.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $676.99 Million | -26.76% |
| 2025 | $924.30 Million | +19.29% |
| 2024 | $774.85 Million | -39.43% |
| 2023 | $1.28 Billion | +15.87% |
| 2022 | $1.10 Billion | -11.36% |
| 2021 | $1.25 Billion | -57.13% |
| 2020 | $2.91 Billion | +137.53% |
| 2019 | $1.22 Billion | -2.07% |
| 2018 | $1.25 Billion | -8.24% |
| 2017 | $1.36 Billion | +159.32% |
| 2016 | $524.87 Million | -29.76% |
| 2015 | $747.27 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Kura Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $676.99 Million USD |
| MoneyControl | $676.99 Million USD |
| MarketWatch | $676.99 Million USD |
| marketcap.company | $676.99 Million USD |
| Reuters | $676.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more